EYENOVIA INC. - COMMO

Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022

20 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Eyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting

19 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results

28 Mar 2022 15:05:00 By Nasdaq GlobeNewswire

Eyenovia to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28

21 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions

15 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Eyenovia Strengthens Balance Sheet with a $15 Million Institutional Capital Investment from Armistice Capital Master Fund Ltd.

04 Mar 2022 06:00:00 By Nasdaq GlobeNewswire

Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission

08 Feb 2022 07:00:03 By Nasdaq GlobeNewswire

Eyenovia Announces Changes to Board of Directors

07 Feb 2022 07:30:00 By Nasdaq GlobeNewswire

Eyenovia Reports Third Quarter 2021 Financial Results

10 Nov 2021 15:05:02 By Nasdaq GlobeNewswire

Eyenovia to Participate in Myopia Panel Discussion at the Eyecelerator@AAO 2021 Meeting

08 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10

05 Nov 2021 14:25:02 By Nasdaq GlobeNewswire

Eyenovia to Report Third Quarter 2021 Results on Thursday, November 11

04 Nov 2021 15:05:03 By Nasdaq GlobeNewswire

Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia

04 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Eyenovia Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product by FDA

25 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Eyenovia Reports Second Quarter 2021 Financial Results

11 Aug 2021 15:05:00 By Nasdaq GlobeNewswire

Eyenovia to Report Second Quarter 2021 Results on Wednesday, August 11

04 Aug 2021 07:00:01 By Nasdaq GlobeNewswire

Eyenovia to Participate in Two Upcoming Investor Conferences

07 Jul 2021 15:01:00 By Nasdaq GlobeNewswire

Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue

15 Jun 2021 07:00:02 By Nasdaq GlobeNewswire

Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia

25 May 2021 08:03:54 By Nasdaq GlobeNewswire

Eyenovia Reports First Quarter 2021 Financial Results

12 May 2021 15:05:01 By Nasdaq GlobeNewswire